Abstract:Diffuse Midline Glioma (DMG) are fatal pediatric brain tumors with no effective systemic therapies. We leveraged network-based methodologies to dissect tumor heterogeneity, discover Master Regulators (MR) representing pharmacologically accessible vulnerabilities of distinct DMG cell states, and validated candidate MR-reversing drugs predicted by the NYS CLIA-certified OncoTarget and OncoTreat algorithms (Cancer Discov 2023) in vivo. We first interrogated single cell DMG regulatory networks generated by ARACNe (Nat Genet 2005) with publicly available gene expression signatures from 3,039 tumor cells across 6 patients using VIPER (Nat Genet 2016) to infer single cell regulatory protein activity. Clustering of cells by protein activity defined 7 patient-independent cell states with distinct MR profiles reflecting known glial lineage markers (OPC-like-S1, OPC-like-S2, OC-like-S1, OC-like-S2, Cycling, AC-like, and AC/OPC-like). We then generated drug-induced differential protein activity from RNAseq profiles following perturbation with 372 oncology drugs in two DMG cell lines that together recapitulate the MR signatures of the cell states and used this to identify drugs that invert tumor MR activity profiles using OncoTreat. Candidate drugs predicted by OncoTarget (inhibitors of individual MRs) and OncoTreat were distinct across the cell states, and we selected five drugs targeting the OPC/cycling-like cells (Trametinib, Dinaciclib, Avapritinib, Mocetinostat, and Etoposide), and four drugs targeting the AC-like cells (Ruxolitinib, Venetoclax, Napabucasin, Larotrectonib) for further validation as these states comprised most tumor cells across patients. We generated single-cell RNAseq for 95,687 cells after 5 days of treatment with either vehicle control (n = 4) or candidate drug (n = 2-3/drug) in subcutaneous SU-DIPG-17 mouse models. We show this model recapitulates cell states seen in patients and confirm reduction in tumor growth and significant depletion of either OPC/cycling-like cells or AC-like cells in line with our drug predictions for 8/9 candidate drugs. We then treated a syngeneic (DIPG4423) orthotopic DMG model with each drug and demonstrate significant differences in survival with Avapritinib, Dinaciclib, and Trametinib. Notably, the combination of drugs targeting OPC/cycling-like and AC-like cells (i.e. Trametinib+Ruxolitinib and Avapritinib+Venetoclax) showed significantly lower tumor volumes after 2 weeks of treatment as compared to vehicles or each drug alone, and significant survival differences for some combinations. This work provides a precision medicine platform to nominate much-needed novel drug combinations addressing DMG tumor heterogeneity for further study to improve outcomes in this devastating disease. Citation Format: Ester Calvo Fernandez, Lorenzo Tomassoni, Xu Zhang, Aleksandar Obradovic, Pasquale Laise, Aaron T. Griffin, Lukas Vlahos, Junqiang Wang, Hanna E. Minns, Diana V. Morales, Christian Simmons, Matthew Gallito, Hong-Jian Wei, Zhiguo Zhang, Robyn Gartrell, Luca Szalontay, Stergios Zacharoulis, Cheng-Chia Wu, Andrea Califano, Jovana Pavisic. Discovery and validation of effective combination therapies targeting cell state-specific master regulator vulnerabilities by network-based protein activity inference in diffuse midline glioma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 5460.

Abstract 3503: New generation drug development from in-silico identification to preclinical evaluation in glioblastoma

A Multistep In Silico Approach Identifies Potential Glioblastoma Drug Candidates via Inclusive Molecular Targeting of Glioblastoma Stem Cells

High-throughput identification of repurposable neuroactive drugs with potent anti-glioblastoma activity

Abstract A015: Predicting efficacious drugs and drug-biomarker relationships for targeted glioblastoma treatment

Repurposing Ivermectin and ATRA as Potential Therapeutics for Glioblastoma Multiforme

Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs

Abstract 6905: A multi-targeted approach to evaluate therapeutic selection and efficacy in preclinical GBM models

Abstract 1666: Novel Glucose Transporter Inhibitors Decrease Glioblastoma Growth and Glucose Uptake

Identification of novel small-molecule inhibitors of glioblastoma cell growth and invasion by high-throughput screening.

Abstract 5846: Inhibiting elements of the proteasome recovery pathway sensitizes glioblastoma to proteasome inhibitors

Abstract LB432: Identification of novel drug targets using the ADAPT biotargeting system on FFPE tissue from patients with glioblastoma multiforme

A molecular screening approach to identify and characterize inhibitors of glioblastoma stem cells

Abstract 3106: Integrated in vitro and machine learning approaches for targeted drug screening in gliomas with concurrent NF1 and ATRX loss

Abstract 6205: Identify drugs for metastatic castration-resistance prostate cancer (mCRPC) patients with high glycolytic activity through in silico approach

Structure-Based Virtual Screening, Molecular Docking, Molecular Dynamics Simulation of EGFR for the Clinical Treatment of Glioblastoma

Abstract 5460: Discovery and validation of effective combination therapies targeting cell state-specific master regulator vulnerabilities by network-based protein activity inference in diffuse midline glioma

Antiretroviral Drug Repositioning for Glioblastoma

DDIS-24. DECREASE IN GLIOBLASTOMA GROWTH IN VITRO WITH TREATMENT OF NOVEL ANALOGS OF GLUCOSE TRANSPORTER INHIBITORS

Repurposing synthetic and natural derivatives induces apoptosis in an orthotopic glioma-induced xenograft model by modulating WNT/β-catenin signaling

Multitarget Potential Drug Candidates for High-Grade Gliomas Identified by Multiple Reaction Monitoring Coupled with In Silico Drug Repurposing

Abstract 2553: Functional precision medicine as a valid tool in glioblastoma clinical practice